Lyon

• A clinical study of MK-2870 in people with stomach cancer (MK-2870-015) Ended recruitment
  2023-505423-31-00 5 2024-08-08 advanced or metastatic gastric adenocarcinoma, gastroesophageal juncti
• PREVENE : Preemptive therapy with Venetoclax for high risk CLL stage A patients, a phase II trial of the FILO Ended recruitment
  2024-513718-37-00 4 2024-08-01 IGHV unmutated patients with high-risk stage A CLL features.
• Phase 2 Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma Ended recruitment
  2023-505177-32-00 4 2024-07-31 Intermediate-high -risk RCC, high-risk RCC who have undergone nephrect
• A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours Ended recruitment
  2023-506228-10-00 7 2024-06-27 Pancreatic Ductal Adenocarcinoma
• A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants with Severe Alopecia Areata Ended recruitment
  2023-505061-82-01 5 2024-06-17 Alopecia Areata
• A clinical trial to look at how ZN-A-1041 alone or ZN-A-1041 plus some approved drugs works to reduce tumor size and how safe these drugs ar … Ended recruitment
  2023-508459-37-00 1 2024-05-28 HER2-positive advanced solid tumours
• Phase Ib Dose Finding Study of [177Lu]Lu-NeoB in Combination with RT and TMZ in Newly Diagnosed Glioblastoma and as a Single Agent in Recurr … Ended recruitment
  2022-502134-10-00 3 2024-05-15 Glioblastoma
• A trial to find out how safe REGN7075 is and how well it works in combination with cemiplimab for participants with advanced cancers Ended recruitment
  2022-501234-37-00 7 2024-05-07 Solid Tumours
• Phase III Trial of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed vs. Investigator’s Choice of the Standard of Care … Ended recruitment
  2023-503231-17-00 5 2024-04-26 Unresectable Pleural Mesothelioma
• A study to assess adverse events and effectiveness of upadacitinib oral tablets in adult and adolescent participants with vitiligo. Ended recruitment
  2023-506195-27-00 5 2024-04-05 non-segmental vitiligo
• A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab i … Ended recruitment
  2023-506948-17-00 5 2024-04-05 Previously Untreated Chronic Lymphocytic Leukemia
• TocilizuMab discontinuAtion in GIant Cell Arteritis Ended recruitment
  2023-505515-21-00 5 2024-04-02 Giant Cell Arteritis
• A phase I, open-label, multi-center study of KFA115 as a single agent and in combination with pembrolizumab in patients with select advanced … Ended recruitment
  2022-502381-25-01 1 2024-03-15 Thymic Carcinoma
• MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer Ended recruitment
  2023-504816-14-00 5 2024-03-08 Endometrial cancer
• PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed … Ended recruitment
  2023-505972-32-00 5 2024-02-26 locally advanced anal squamous cell carcinoma
• Patient Preference Study of SC Pembrolizumab versus IV Pembrolizumab with hyaluronidase (MK-3475A) in multiple cancer types Ended recruitment
  2023-506017-22-00 4 2024-02-16 Melanoma, Renal Cell Carcinoma, Non-small cell lung cancer
• ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function (Varvara) Ended recruitment
  2022-503091-89-00 4 2024-02-15 Delayed graft function
• An Open-Label Multicenter Phase 1b Study of Tolinapant (ASTX660) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative … Ended recruitment
  2024-511963-28-00 3 2023-12-19 Neoadjuvant therapy in locally-advanced rectal cancer
• A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Par … Ended recruitment
  2022-501396-62-00 5 2023-12-12 Relapsed Refractory Multiple Myeloma
• Public Title: Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Participants with M … Ended recruitment
  2022-502975-45-00 5 2023-12-12 Metastatic leiomyosarcoma
• Phase I study evaluating the safety and efficacy of MEDI5752 in combination with stereotactic radiotherapy in patients with metastatic sarco … Ended recruitment
  2024-515551-38-00 3 2023-12-12 Metastatic soft tissue sarcoma
• A Phase 2, open-label, multi-centre, multi-national interventional trial to evaluate the efficacy and safety of erdafitinib (ERDA) monothera … Ended recruitment
  2024-512573-27-01 4 2023-12-11 Muscle-invasive bladder cancer (MIBC)
• Phase 3 study of perioperative dostarlimab in participants with untreated T4N0 or stage III dMMR/MSI-H resectable colon cancer Ended recruitment
  2023-503265-27-00 5 2023-11-23 Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Co
• A Study of an Intermittent ADT Approach with Apalutamide Monotherapy in Participants with mCSPC Ended recruitment
  2022-502686-24-00 5 2023-11-22 Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Showing 505–528 of 875 trials